文献速递乳腺癌

激素受体阳性淋巴结阴性乳腺癌中21基因复发评分的种族差异

Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
PubMed 文献 · J Clin Oncol · 2018-01-17

该研究基于底特律大都会癌症监测系统,纳入2010至2014年确诊的激素受体阳性、HER2阴性、淋巴结阴性浸润性乳腺癌女性2216例(非西班牙裔白人1824例,非西班牙裔黑人392例),比较21基因复发评分(RS)的种族差异。调整年龄、临床分期、分级和组织学后,非西班牙裔黑人高危肿瘤风险仍更高(OR 1.75,95%CI 1.18-2.59)。

要点

  • 非西班牙裔黑人乳腺癌患者21基因RS平均分显著高于非西班牙裔白人。
  • 高危RS比例非西班牙裔黑人为14.8%,白人为8.3%。
  • 差异限于65岁以下患者,调整混杂因素后高危风险仍高。

核心结论

  • 符合21基因RS检测临床标准的非西班牙裔黑人乳腺癌患者,其肿瘤远处复发估计风险高于非西班牙裔白人。

研究设计与样本

  • 基于底特律大都会癌症监测系统的回顾性队列研究,纳入2010至2014年确诊的激素受体阳性、HER2阴性、淋巴结阴性浸润性乳腺癌女性2216例(非西班牙裔白人1824例,非西班牙裔黑人392例)。

主要发现

  • 调整年龄、临床分期、肿瘤分级和组织学后,非西班牙裔黑人高危肿瘤风险仍更高(OR 1.75,95%CI 1.18至2.59)。

关键数值与推荐

  • 21基因RS风险分类标准:低危<18,中危18至30,高危≥31。

临床怎么用

  • 临床解读非西班牙裔黑人患者的21基因RS时需注意其评分可能偏高,高危比例更高。
  • 尤其对65岁以下非西班牙裔黑人患者,应结合RS评估远处复发风险并谨慎制定治疗决策。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The 21-gene recurrence score (RS) breast cancer assay is clinically used to quantify risk of 10-year distant recurrence by category (low, < 18; intermediate, 18 to 30; high, ≥ 31) for treatment management among women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative, lymph node-negative breast cancer. Although non-Hispanic black (NHB) women have worse prognosis compared with non-Hispanic white (NHW) women, the equivalency of 21-gene RS across racial groups remains unknown. Patients and Methods Using the Metropolitan Detroit Cancer Surveillance System, we identified women who were diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative, lymph node-negative invasive breast cancer between 2010 and 2014. Multinomial logistic regression was used to quantify racial differences in 21-gene RS category. Results We identified 2,216 women (1,824 NHW and 392 NHB) with invasive breast cancer who met clinical guidelines for and underwent 21-gene RS testing. The mean RS was significantly higher in NHBs compared with NHWs (19.3 v 17.0, respectively; P = .0003), where NHBs were more likely to present with high-risk tumors compared with NHWs (14.8% v 8.3%, respectively; P = .0004). These differences were limited to patients younger than 65 years at diagnosis, among whom NHBs had significantly higher RS compared with NHWs (20 to 49 years: 23.6 v 17.3, respectively; P < .001 and 50 to 64 years: 19.6 v 17.4, respectively; P = .023). NHBs remained more likely to have high-risk tumors compared with NHWs after adjusting for age, clinical stage, tumor grade, and histology (odds ratio [OR], 1.75; 95% CI, 1.18 to 2.59). Conclusion NHBs who met clinical criteria for 21-gene RS testing had tumors with higher estimated risks of distant recurrence compared with NHWs. Further study is needed to elucidate whether differences in recurrence are observed for these women, which would have clinical implications for 21-gene RS calibration and treatment recommendations in NHB patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Holowatyj AN, Cote ML, Ruterbusch JJ, et al. Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer. J Clin Oncol. 2018. PMID: 29341832. doi:10.1200/JCO.2017.74.5448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。